Valuation: VolitionRx Limited

Market Cap 11.25M 9.85M 9.07M 8.42M 15.99M 1.07B 16.21M 109M 42.26M 527M 42.23M 41.31M 1.83B P/E 2026 *
-0.61x
P/E 2027 * -0.97x
Enterprise Value 11.25M 9.85M 9.07M 8.42M 15.99M 1.07B 16.21M 109M 42.26M 527M 42.23M 41.31M 1.83B EV / Sales 2026 *
4.54x
EV / Sales 2027 * 1.96x
Free-Float
91.38%
Yield 2026 *
-
Yield 2027 * -
1 day-3.57%
1 week-4.93%
1 month-24.58%
3 months-60.08%
6 months-75.61%
Current year-73.59%
1 week 1.32
Extreme 1.32
1.48
1 month 1.17
Extreme 1.17
1.56
Current year 1.17
Extreme 1.17
7.73
1 year 1.17
Extreme 1.17
16
3 years 1.17
Extreme 1.17
31
5 years 1.17
Extreme 1.17
82.8
10 years 1.17
Extreme 1.17
136.8
Manager TitleAgeSince
Chief Executive Officer 55 05/10/2011
Director of Finance/CFO 56 31/01/2021
Chief Tech/Sci/R&D Officer 49 31/03/2024
Director TitleAgeSince
Director/Board Member 55 05/10/2011
Director/Board Member 77 05/10/2011
Director/Board Member 64 08/10/2019
Date Insider Type Main position Quantity % Market Cap.
03-16Tax

Chief Technology Officer

5,310 0.0039%
03-16Tax

Executive/Senior Manager

5,251 0.0039%
03-16Tax

General Counsel

7,003 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
-3.57%-4.93%-90.88%-95.04% 11.25M
+1.60%-3.65%+110.81%+149.76% 4.63B
+1.46%+0.47%+82.20%+255.37% 3.44B
-1.23%+0.78%-26.36%-39.01% 2.04B
-2.78%-0.48%+139.43%-38.47% 1.87B
-0.45%-0.75%+51.04%+247.19% 1.5B
-2.32%-7.67%+120.97%-51.12% 870M
-1.02%-4.60%-9.78%+45.98% 864M
+0.64%+5.55%-34.19%-14.89% 501M
+0.24%-7.16%+3.31% - 473M
Average -0.74%-2.18%+34.66%+51.09% 1.62B
Weighted average by Cap. +0.09%-1.35%+71.56%+113.02%

Financials

2026 *2027 *
Net sales 2.48M 2.17M 2M 1.86M 3.52M 236M 3.57M 23.92M 9.31M 116M 9.3M 9.1M 402M 5.73M 5.02M 4.62M 4.29M 8.15M 547M 8.26M 55.36M 21.55M 268M 21.53M 21.06M 931M
Net income -22.2M -19.45M -17.91M -16.62M -31.57M -2.12B -32M -214M -83.44M -1.04B -83.38M -81.55M -3.6B -19.62M -17.18M -15.83M -14.69M -27.9M -1.87B -28.27M -189M -73.73M -919M -73.68M -72.06M -3.18B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
67
Date Price Change Volume
06/07/26 US$1.350 -3.57% 176,076
02/07/26 US$1.400 +2.94% 208,730
01/07/26 US$1.360 +0.74% 201,077
30/06/26 US$1.350 -4.93% 163,419
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.350USD
Average target price
16.97USD
Spread / Average Target
+1,156.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock